PIM
RIGL icon

Platinum Investment Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Platinum Investment Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-6,730
Closed -$240K – 88
2013
Q3 		$240K Hold
6,730
– – ﹤0.01% 82
2013
Q2 		$224K Buy
+6,730
New +$305K ﹤0.01% 80

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Platinum Investment Management's RIGL Position: Q4 2013 in Review

Platinum Investment Management sold out of Rigel Pharmaceuticals (RIGL) in Q4 2013, closing a stake of 6,730 shares — an estimated $240K sold.

Platinum Investment Management first reported a position in RIGL in Q2 2013 and held it in 2 quarters. The position peaked at $240K in Q3 2013. 100 funds tracked by Wall St. Rank hold RIGL as of Q4 2013.

  • Platinum Investment Management reported no remaining Rigel Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Platinum Investment Management sold 6,730 Rigel Pharmaceuticals shares in Q4 2013, an estimated $240K.
  • Platinum Investment Management first reported a position in Rigel Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Platinum Investment Management's Rigel Pharmaceuticals position peaked at $240K in Q3 2013.
  • 100 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2013.

Based on Platinum Investment Management's 13F filing for Q4 2013, filed 13 Feb 2014.